1 unchanged sentence
Securities Trading Plans of Directors and Executive Officers
−Removed: During the three months ended September 30, 2023, none of our directors or executive officers adopted or terminated any contract , instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended.
+Added: During the three months ended March 31, 2024, none of our directors or executive officers adopted or terminated any contract , instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended.
The exhibits listed on the accompanying index to exhibits are filed or incorporated by reference (as stated therein) as part of this Quarterly Report on Form 10-Q.
5 unchanged sentences
Specimen Common Stock Certificate.
−Removed: Executive Severance Plan, as amended.
−Removed: Amendment 1 to the License and Collaboration Agreement with Eli Lilly and Company.
+Added: Asset Purchase Agreement with Blueprint Medicines Corporation, dated February 22, 2024 .
+Added: Amendment No.
+Added: 2 to the License and Collaboration Agreement with Eli Lilly and Company, dated March 11, 2024.
+Added: Fourth Amendment to the Credit and Security Agreement with MidCap Financial Trust, dated April 11, 2024.
+Added: Rigel Pharmaceuticals, Inc.
+Added: Inducement Plan, as amended .
Certification required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.
9 unchanged sentences
Filed herewith
−Removed: ˄ Certain marked information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private and confidential.
+Added: ˄ Certain marked information has been redacted from this exhibit pursuant to Item 601(b)(1)(iv) of Regulation S-K because it is both not material and is the type that the registrant treats as private and confidential.
+Added: An unredacted copy of this exhibit will be furnished supplementally to the SEC upon request.
* The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C.
10 unchanged sentences
(Principal Executive Officer)
−Removed: November 7, 2023
Chief Financial Officer
(Principal Financial Officer)
−Removed: November 7, 2023
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.